Nama's AI scorecard currently rates Inspire Medical Systems Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is INSP's P/E ratio?

Inspire Medical Systems trades at a trailing price-to-earnings ratio of 31.5.

When does INSP report earnings?

Inspire Medical Systems's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.91.

What is the INSP price target?

The median analyst price target from 16 analysts is $69.50, with a range of $40.00 – $97.00.

Is INSP Shariah compliant?

Nama's AAOIFI-style screen reads Inspire Medical Systems as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Inspire Medical Systems (INSP)

Healthcare · Medical Devices · NYSE

Inspire Medical Systems (INSP) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.85B, a trailing price-to-earnings ratio of 31.5 and a free-cash-flow yield of 4.1%. Over the most recent reported fiscal year, revenue grew 13.6% and free cash flow per share fell 13.9%. Nama's AI scorecard rates it Buy, 6.9 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 6.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -19.5% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-80.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.85B
Trailing P/E	31.5
Price / book	2.2
Price / sales	2.1
FCF yield	4.1%
Dividend yield	—
Gross margin	86.1%
Operating margin	6.0%
Net margin	15.0%
Revenue growth (YoY)	+13.6%
Revenue growth (3-yr annual)	+30.8%
EPS growth (YoY)	+49.1%
FCF/share growth (YoY)	-13.9%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

INSP earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate $0.91). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$0.14	$0.09	+55.6%	$206.69M
Q2 2026	Aug 3, 2026	$0.14	-$0.25	+156.0%	$200.58M
Q1 2026	May 4, 2026	$0.10	-$0.26	+138.5%	$204.58M
Q4 2025	Feb 11, 2026	$1.65	$0.68	+142.7%	$269.08M

INSP analyst price target

Median target $69.50 from 16 analysts, ranging $40.00 – $97.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live INSP data on Nama Insights →

INSP FAQ

Is INSP a buy?: Nama's AI scorecard currently rates Inspire Medical Systems Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is INSP's P/E ratio?: Inspire Medical Systems trades at a trailing price-to-earnings ratio of 31.5.
When does INSP report earnings?: Inspire Medical Systems's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.91.
What is the INSP price target?: The median analyst price target from 16 analysts is $69.50, with a range of $40.00 – $97.00.
Is INSP Shariah compliant?: Nama's AAOIFI-style screen reads Inspire Medical Systems as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.